Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bexarotene; Methotrexate
  • Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides
  • Focus Registrational; Therapeutic Use
  • Acronyms ALCANZA
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 29 Mar 2021 Results of an exploratory post-hoc sub-analysis assessing responses in MF subset of patients by CD30 or large cell transformation published in the European Journal of Cancer
    • 02 Jun 2020 Results reporting patient-reported quality of life published in the European Journal of Cancer
    • 06 Nov 2019 Results of an analysis of Eq-5D and Skindex- 29 data collected from the Alcanza trial presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top